Author name: Leonardo Arias

Post-acute care is healthcare’s biggest blind spot — and a major opportunity.

Agentic AI transforms healthcare through autonomous agents handling scheduling, documentation and coding at HIMSS 2026.

Utilizing AI to structure all contract and invoice data, healthcare leaders are creating digital twins for spend to create a permanent advantage.

En la historia de la ciencia del siglo XX, Max Perutz destaca por su discreción e influencia. Pionero en el estudio de las proteínas y figura clave en el desarrollo de la biología molecular, su trabajo permitió comprender cómo funcionan los mecanismos más b& …

Durante más de 3.500 millones de años, la vida en la Tierra ha evolucionado mediante un mismo lenguaje básico: el ADN. Este sistema, basado en cuatro “letras” químicas —A, T, C y G— ha sido capaz de generar desde bacterias hasta cerebros humanos. P …

Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly advance specific, age-related diseases, according to two investors in a discussion with BioSpace.

El mundo está cada vez más preocupado por la sostenibilidad, la seguridad alimentaria y el impacto ambiental de lo que comemos. En ese contexto, una alternativa gana terreno con rapidez: los insectos como fuente de proteínas. Aunque para muchas culturas occidentales todav&iacute …

Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential billion-dollar market and banking on local delivery and the small amount of drug required to overcome key safety concerns.

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and manufacturing-ready reagent platforms are reshaping regenerative medicine and oncology. Recombinant antibodies and drug targets, e.g. endotoxin-free proteins, transmembrane proteins, and site-specifically labeled biomolecules are emerging as indispensable enablers of reproducibility, mechanistic insight, and clinical-scale success.

The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma leaders try to decode the criteria for investigational or approved drugs to receive a voucher.